DGAP-News: PAION AG / Key word(s): Change of Personnel
JUERGEN RATHS, MD APPOINTED AS CHIEF OPERATING OFFICER AT PAION AG
27.08.2015 / 14:00
---------------------------------------------------------------------
JUERGEN RATHS, MD APPOINTED AS CHIEF OPERATING OFFICER AT PAION AG
- New COO brings wealth of experience in international product launches
- Responsible for the establishment of an efficient commercial structure
Aachen (Germany), 27 August 2015 - PAION AG, a Specialty Pharma Company
(ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8),
announces that Dr. Juergen Raths (59) has been appointed by the Supervisory
Board as a new member of the Management Board of PAION AG and will be Chief
Operating Officer with effect from 1 September 2015. Dr. Raths has been
working for PAION as a consultant since 2014 and will be responsible for
the establishment of the commercial structure to serve anesthetists in
Europe and around the world.
Dr. Raths has over 25 years of experience in the European and global pharma
business, with positions held in medical sales and marketing as well as
general management in Europe and the U.S He was Associate Partner with
Executive Insight, a Zurich-based pharma consultancy firm, focusing on
biotech, pharma and medical device companies. Dr. Raths focused on
supporting Pharma companies entering the European market. He formerly
served as President and CEO of private specialty pharmaceutical company
Correvio International in Geneva as well as President and CEO of publicly
traded Arpida AG based in Basel. Dr. Raths spent 18 years with Eli Lilly
and Company in various senior executive roles including Head Critical Care
Europe, and he spent three years at Corporate Headquarters in Indianapolis
in Health Economics and New Product Planning. He holds an MD from the
University of Bonn. Dr. Raths brings to PAION exceptional leadership
experience in company formation, change management and global business
development.
Dr. Jörg Spiekerkötter, Chairman of the Supervisory Board of PAION AG,
explained why Dr. Raths was the candidate of choice: "Our decision to
appoint Dr. Raths as COO aligns with our strategy to broaden the know-how
of the executive management of PAION for the future and to transform PAION
into a commercial-stage company. We are bringing on board an experienced
business executive with a strong background in global product launches. I
wish him every success in his new function."
"I have known Jürgen for many years and with his deep experience in
building up commercial structures he was our favorite candidate. Juergen
will support the company on its path through Phase III development,
approval and commercialization of Remimazolam", commented Dr. Wolfgang
Söhngen, CEO of PAION AG.
###
About PAION
PAION AG is a publicly-listed Specialty Pharma Company headquartered in
Aachen, Germany, with further sites in Cambridge, UK, and New Jersey, U.S.
The company has a track record of developing hospital-based treatments for
which there is substantial unmet medical need. PAION's strategy is to
participate in the commercialization of Remimazolam and extend its business
with a focus on anesthesia/critical care products. Remimazolam is the
building block for its future marketing activities.
For more information please visit www.paion.com
PAION Contact
Ralf Penner
Director Investor Relations / Public Relations
PAION AG
Martinstrasse 10-12
52062 Aachen - Germany
Phone: +49 241 4453-152
E-mail: r.penner@paion.com
www.paion.com
Disclaimer:
This release contains certain forward-looking statements concerning the
future business of PAION AG. These forward-looking statements contained
herein are based on the current expectations, estimates and projections of
PAION AG's management as of the date of this release. They are subject to a
number of assumptions and involve known and unknown risks, uncertainties
and other factors. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ materially from any
future results and developments expressed or implied by such
forward-looking statements. Considering the risks, uncertainties and other
factors involved, recipients should not rely unreasonably upon these
forward-looking statements. PAION AG has no obligation to periodically
update any such forward-looking statements to reflect future events or
developments.
---------------------------------------------------------------------
27.08.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: PAION AG
Martinstr. 10-12
52062 Aachen
Germany
Phone: +49 (0)241-4453-0
Fax: +49 (0)241-4453-100
E-mail: info@paion.com
Internet: www.paion.com
ISIN: DE000A0B65S3
WKN: A0B65S
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
389933 27.08.2015
DGAP-News: JUERGEN RATHS, MD APPOINTED AS CHIEF OPERATING OFFICER AT PAION AG
| Quelle: EQS Group AG